References
- Tsivian M, Moreira DM, Caso JR, et al. Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol. [Internet]. 2011;29(15):2027–2031. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21502558.
- Macleod LC, Hotaling JM, Wright JL, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol. [Internet]. 2013;190(5):1657–1661. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4420476&tool=pmcentrez&rendertype=abstract.
- Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. [Internet]. 2016;9:45–52. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4790506&tool=pmcentrez&rendertype=abstract.
- Haddad AQ, Margulis V. Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol. [Internet]. 2015;12(5):253–262. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25868564.
- Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. [Internet]. 2010;183(4):1309–1316. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20171681.
- Patard J-J, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. [Internet]. 2005;23(12):2763–2771. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15837991.
- Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. [Internet]. 1982;6(7):655–663. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7180965.
- Creighton CJ, Morgan M, Gunaratne PH, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi:10.1038/nature12222.
- Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. [Internet]. 1993;260(5112):1317–1320. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8493574.
- Zbar B, Brauch H, Talmadge C, et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. [Internet]. 1987;327(6124):721–724. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2885753.
- Tanimoto K, Makino Y, Pereira T, et al. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. [Internet]. 2000;19(16):4298–4309. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=302039&tool=pmcentrez&rendertype=abstract.
- Keefe SM, Nathanson KL, Rathmell WK. The molecular biology of renal cell carcinoma. Semin Oncol. [Internet]. 2013;40(4):421–428. Available from: http://www.sciencedirect.com/science/article/pii/S009377541300081X.
- Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. [Internet]. 2007;109(11):2257–2267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17440983.
- Simon JM, Hacker KE, Singh D, et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res. [Internet]. 2014;24(2):241–250. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3912414&tool=pmcentrez&rendertype=abstract.
- Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. [Internet]. 2014;349(nov10_11):g4797. Available from: http://www.bmj.com.proxy.library.vanderbilt.edu/content/349/bmj.g4797.long.
- Janiszewska AD, Poletajew S, Wasiutyński A. Spontaneous regression of renal cell carcinoma. Contemp Oncol (Poznań, Poland). [Internet]. 2013;17(2):123–127. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3685371&tool=pmcentrez&rendertype=abstract.
- Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. [Internet]. 1997;158(5):1691–1695. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9334580.
- Melichar B, Vaneckova J, Moravek P, et al. Spontaneous regression of renal cell carcinoma lung metastases in a patient with psoriasis. Acta Oncol. [Internet]. 2009;48(6):925–927. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19360505.
- Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. [Internet]. 2001;345(23):1655–1659. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11759643.
- Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (London, England). [Internet]. 2001;358(9286):966–970. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11583750.
- Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. [Internet]. 1995;13(3):688–696. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7884429.
- Charles A, Janeway J, Travers P, et al. Principles of innate and adaptive immunity. 2001; New York: Garland Science.
- Sha WC, Nelson CA, Newberry RD, et al. Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature. [Internet]. 1988;336(6194):73–76. Available from: http://www.nature.com/doifinder/10.1038/336073a0.
- Jenkins MK, Ashwell JD, Schwartz RH. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol. [Internet]. 1988;140(10):3324–3330. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2834436.
- Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. [Internet]. 2013;94(1):25–39. Available from: /pmc/articles/PMC3685017/?report=abstract.
- Gunturi A, McDermott DF. Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol. [Internet]. 2014;15(1):137–146. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24504486.
- Rathmell JC, Fox CJ, Plas DR, et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. [Internet]. 2003;23(20):7315–7328. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=230333&tool=pmcentrez&rendertype=abstract.
- Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. [Internet]. 2008;26:677–704. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18173375.
- Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. [Internet]. 2016;11(2):143–148. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26429561.
- Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. [Internet]. 2016;139:396–403. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26945902.
- Messai Y, Gad S, Noman MZ, et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status. Eur Urol. [Internet]. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26707870.
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. [Internet]. 2011;144(5):646–674. Available from: http://www.cell.com/article/S0092867411001279/fulltext.
- Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81.
- Jilaveanu LB, Shuch B, Zito CR, et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer. [Internet]. 2014;5(3):166–172. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3931264&tool=pmcentrez&rendertype=abstract.
- Sittig SP, Køllgaard T, Grønbæk K, et al. Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. Oncoimmunology. [Internet]. 2013;2(9):e26014. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3820815&tool=pmcentrez&rendertype=abstract.
- Devaud C, Westwood JA, Teng MW, et al. Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors. Oncoimmunology. [Internet]. 2014;3(11):e963395. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4368122&tool=pmcentrez&rendertype=abstract.
- Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. [Internet]. 1999;11(2):141–151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10485649.
- Dong H, Zhu G, Tamada K, et al. B7-H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes. Immunity. [Internet]. 2004;20(3):327–336. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15030776.
- Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma. Annu Rev Immunol. [Internet]. 1997;15:749–795. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9143706.
- Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. [Internet]. 2007;30(8):825–830. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2134980&tool=pmcentrez&rendertype=abstract.
- Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. [Internet]. 2010;28(19):3167–3175. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20516446.
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. [Internet]. 2012;366(26):2443–2454. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3544539&tool=pmcentrez&rendertype=abstract.
- Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. [Internet]. 2008;26(36):5950–5956. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19018089.
- McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. [Internet]. 2015;33(18):2013–2020. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25800770.
- Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. [Internet]. 2015;33(13):1430–1437. Available from: http://jco.ascopubs.org.proxy.library.vanderbilt.edu/content/33/13/1430.long.
- Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. [Internet]. 2015;373(19):150925150201006. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26406148.
- Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. [Internet]. 2012;366(26):2455–2465. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3563263&tool=pmcentrez&rendertype=abstract.
- McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase IA study. J Clin Oncol. [Internet]. 2016;34:833–842. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26755520.
- Albiges L, Fay AP, Xie W, et al. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. Eur J Cancer. [Internet]. 2015;51(17):2580–2586. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26346135.
- Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. [Internet]. 2016;4(1):3. Available from: http://www.immunotherapyofcancer.org/content/4/1/3.